InvivoGen
InvivoGen was founded in 1997 by scientists with technical expertise and creative excellence stemming from a longstanding history in microbiology. InvivoGen's unparalleled skill in microbial fermentation enables them to provide a wide range of biological molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest collection of pattern recognition receptor agonists derived from a wide range of micro-organisms.
More information at https://www.invivogen.com.
InvivoGen
RIG-I knockout NF-kB-SEAP & IRF-Lucia reporter lung carcinoma cells
InvivoGen
A549 lung carcinoma cells expressing human ACE2 and human TMPRSS2
InvivoGen
SEAP reporter HEK293 cells expressing human ACE2 and TMPRSS2a
